๐April News Round up ๐๏ธ Business Year 3 Vision Executives business year grew significantly in its...
๐๐๐ซ๐๐ค ๐ญ๐จ ๐๐๐ช๐ฎ๐ข๐ซ๐ ๐๐ฒ๐๐๐ข๐จ๐ญ๐๐๐ก ๐ข๐ง ๐ ๐ซ๐จ๐ฎ๐ง๐๐๐ซ๐๐๐ค๐ข๐ง๐ $3 ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐๐๐ฅ: ๐ ๐๐๐ฃ๐จ๐ซ ๐๐๐๐ฉ ๐ข๐ง๐ญ๐จ ๐๐ฉ๐ก๐ญ๐ก๐๐ฅ๐ฆ๐ข๐๐ฌ
๐ฒMerck is set to acquire Eyebiotech Limited (EyeBio) in a deal worth up to $3 billion, marking a significant expansion into the ophthalmic industry. The agreement includes an upfront payment of $1.3 billion in cash and up to $1.7 billion in development, regulatory, and commercial milestone payments.
๐คEyeBio, co-founded by Dr. David R. Guyer, focuses on developing treatments for retinal disease. With Merckโs resources and infrastructure, EyeBio will be well-positioned to advance its investigational pipeline. This acquisition strengthens Merckโs portfolio and underscores its commitment to addressing unmet medical needs in ophthalmology.
